• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Arvinas Inc. filed SEC Form 8-K: Leadership Update

    6/6/25 4:22:52 PM ET
    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ARVN alert in real time by email
    arvn-20250604
    0001655759FALSE00016557592025-06-042025-06-04

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
    __________________
    FORM 8-K
    __________________
    CURRENT REPORT
    Pursuant to Section 13 or 15(d)
    of the Securities Exchange Act of 1934
    Date of Report (Date of earliest event reported): June 4, 2025
    __________________
    Arvinas, Inc.
    (Exact name of registrant as specified in its charter)
    __________________
    Delaware001-3867247-2566120
    (State or other jurisdiction
    of incorporation)
    (Commission
    File Number)
    (IRS Employer
    Identification No.)
    5 Science Park
    395 Winchester Ave.
    New Haven, Connecticut
    06511
    (Address of principal executive offices)(Zip Code)
    Registrant’s telephone number, including area code: (203) 535-1456
    Not applicable
    (Former Name or Former Address, if Changed Since Last Report)
    __________________
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
    oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to Section 12(b) of the Act:
    Title of each class
    Trading
    Symbol(s)
    Name of each exchange
    on which registered
    Common stock, par value $0.001 per shareARVN
    The Nasdaq Stock Market LLC
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company o
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o



    Item 5.02     Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
    On June 4, 2025, Ian Taylor, Ph.D., President of Research and Development of Arvinas, Inc. (the “Company”), notified the Company of his decision to resign his employment with the Company and retire, effective June 6, 2025 (the “Resignation Date”). On the Resignation Date, in connection with his resignation, Dr. Taylor and the Company entered into a Consulting Agreement, pursuant to which Dr. Taylor has agreed to provide consulting and advisory services to the Company for one year from the Resignation Date (the “Consulting Period”), unless earlier terminated by the Company or Dr. Taylor with at least 10 business days' prior written notice. Dr. Taylor plans to remain as chair of the Company’s Scientific Advisory Board. Pursuant to the Consulting Agreement, Dr. Taylor will be paid an hourly rate for his services during the Consulting Period.




    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
    ARVINAS, INC.
    Date: June 6, 2025By:/s/ Andrew Saik
    Andrew Saik
    Chief Financial Officer

    Get the next $ARVN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ARVN

    DatePrice TargetRatingAnalyst
    6/2/2025$9.00Outperform → Market Perform
    Leerink Partners
    5/5/2025$11.00Buy → Hold
    Truist
    5/2/2025$10.00Buy → Hold
    Jefferies
    5/2/2025Buy → Hold
    TD Cowen
    3/13/2025$70.00 → $15.00Buy → Neutral
    Goldman
    3/12/2025$57.00 → $12.00Outperform → Neutral
    Wedbush
    3/11/2025Outperform → Perform
    Oppenheimer
    12/10/2024$69.00Buy
    BTIG Research
    More analyst ratings

    $ARVN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer

      – This submission is supported by the pivotal Phase 3 VERITAC-2 clinical trial, results of which were recently presented at the 2025 American Society for Clinical Oncology Annual Meeting and published in The New England Journal of Medicine – – VERITAC-2 data support vepdegestrant as a potential treatment option in patients with ESR1m ER+/HER2- advanced or metastatic breast cancer – NEW HAVEN, Conn., June 06, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) with its partner Pfizer Inc. (NYSE:PFE), for vepdegestrant for the treatment of patients with ER-positive (ER+)/human e

      6/6/25 7:00:03 AM ET
      $ARVN
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the 2025 European Hematology Association (EHA) Annual Meeting

      – Company to showcase preclinical studies of ARV-393, an investigational oral PROTAC BCL6 degrader, as a single agent in models of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type (AITL) and transformed follicular lymphoma, and in combination with small molecule inhibitors in models of diffuse large B-cell lymphoma – NEW HAVEN, Conn., June 05, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today announced that new preclinical data for ARV-393 will be presented at the European Hematology Association (EHA) meeting, June 12-15, 2025 in Milan, Italy. ARV

      6/5/25 8:28:29 AM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer

      Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median progression-free survival when compared to fulvestrant in second line-plus patients with an estrogen receptor 1 mutationVepdegestrant was generally well tolerated, with few discontinuations and low rates of gastrointestinal-related adverse events Vepdegestrant is the first and only PROteolysis TArgeting Chimera (PROTAC) evaluated in a Phase 3 clinical trial and the first to show benefit in patients with breast cancerData to be featured in a late-breaking oral presentation at ASCO and simultaneously published in the New England Journal of MedicineArvinas will host a conference call t

      5/31/25 8:00:50 AM ET
      $ARVN
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARVN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Accounting Officer Loomis David K was granted 11,825 shares, increasing direct ownership by 63% to 30,688 units (SEC Form 4)

      4 - ARVINAS, INC. (0001655759) (Issuer)

      5/13/25 5:18:50 PM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Saik Andrew was granted 59,600 shares, increasing direct ownership by 54% to 170,101 units (SEC Form 4)

      4 - ARVINAS, INC. (0001655759) (Issuer)

      5/13/25 5:17:50 PM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Scientific Officer Cacace Angela M was granted 59,600 shares, increasing direct ownership by 61% to 156,831 units (SEC Form 4)

      4 - ARVINAS, INC. (0001655759) (Issuer)

      5/13/25 5:16:44 PM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARVN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Arvinas Inc.

      SC 13G/A - ARVINAS, INC. (0001655759) (Subject)

      11/14/24 1:22:38 PM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Arvinas Inc.

      SC 13G/A - ARVINAS, INC. (0001655759) (Subject)

      11/14/24 7:00:23 AM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Arvinas Inc.

      SC 13G/A - ARVINAS, INC. (0001655759) (Subject)

      9/10/24 10:30:07 AM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARVN
    SEC Filings

    See more
    • Arvinas Inc. filed SEC Form 8-K: Leadership Update

      8-K - ARVINAS, INC. (0001655759) (Filer)

      6/6/25 4:22:52 PM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arvinas Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - ARVINAS, INC. (0001655759) (Filer)

      6/6/25 7:02:07 AM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arvinas Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - ARVINAS, INC. (0001655759) (Filer)

      6/2/25 6:12:38 AM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARVN
    Financials

    Live finance-specific insights

    See more
    • Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer

      Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median progression-free survival when compared to fulvestrant in second line-plus patients with an estrogen receptor 1 mutationVepdegestrant was generally well tolerated, with few discontinuations and low rates of gastrointestinal-related adverse events Vepdegestrant is the first and only PROteolysis TArgeting Chimera (PROTAC) evaluated in a Phase 3 clinical trial and the first to show benefit in patients with breast cancerData to be featured in a late-breaking oral presentation at ASCO and simultaneously published in the New England Journal of MedicineArvinas will host a conference call t

      5/31/25 8:00:50 AM ET
      $ARVN
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arvinas Reports First Quarter 2025 Financial Results and Provides Corporate Update

      – Reported positive topline results from the Phase 3 VERITAC-2 trial that support global regulatory filings – – Presented first-in-human data for the Company's first neuroscience program with ARV-102 showing blood-brain barrier penetration and central and peripheral LRRK2 degradation – – Announced the re-prioritization of its vepdegestrant development plan and research portfolio and initiated cost reductions, including a workforce reduction of approximately one-third, to extend the Company's cash runway into the second half of 2028 – – Company to host conference call today at 8:00 a.m. ET – NEW HAVEN, Conn., May 01, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clin

      5/1/25 7:00:24 AM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arvinas to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

      NEW HAVEN, Conn., April 28, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today announced that management will review first quarter 2025 financial results and provide a corporate update during a live webcast on Thursday, May 1, 2025, at 8:00 a.m. ET. The webcast can be accessed under "Events and Presentations" on the investor page of the Arvinas website. A replay of the webcast will be available on the Arvinas website at www.arvinas.com following the completion of the event. About ArvinasArvinas (NASDAQ:ARVN) is a clinical-stage biotechnology company dedicated to

      4/28/25 7:00:00 AM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARVN
    Leadership Updates

    Live Leadership Updates

    See more
    • Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update

      – Completed enrollment in the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting; continued enrollment globally in multiple clinical trials of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting– – Completion of enrollment in VERITAC-2 expected in 4Q24 and topline data readout now expected 4Q24/1Q25 – – Received $150 million upon close of ARV-766 license agreement and sale of preclinical AR-V7 program to Novartis; potential for up to an additional $1.01 billion based on achievement of development, regulatory and commercial milestones and future royalties – – Strengthened executive team with the appointm

      7/30/24 7:00:00 AM ET
      $ARVN
      $NVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200

      Director Dr. Malte Peters named Chief Executive Officer and Director Terry Coelho named Executive Vice President and Chief Financial OfficerCompany is conducting a review of its business operations and strategy to determine best path to create shareholder value and realize the full potential of HB-200Sean Cassidy appointed to the Board of Directors NEW YORK and VIENNA, July 22, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK) ("HOOKIPA" or the "Company"), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the appointment of Directors Dr. Malte Peters as Chief Executive Officer and Terry Coelho as Executive Vice Pr

      7/22/24 8:30:00 AM ET
      $ARVN
      $GMDA
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer

      - Awards Mr. Saik an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) - NEW HAVEN, Conn., June 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the appointment of Andrew Saik to the role of Chief Financial Officer and Treasurer reporting to Chairperson, Chief Executive Officer, and President, John Houston, Ph.D. "It is a pleasure to welcome Andrew as our new Chief Financial Officer," said John Houston, Ph.D., Chairperson, Chief Executive Officer, and President at Arvinas. "Andrew is a seasoned executive in biopharma finance with extensive

      6/24/24 4:37:13 PM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARVN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Arvinas downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded Arvinas from Outperform to Market Perform and set a new price target of $9.00

      6/2/25 8:41:53 AM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arvinas downgraded by Truist with a new price target

      Truist downgraded Arvinas from Buy to Hold and set a new price target of $11.00

      5/5/25 8:28:44 AM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arvinas downgraded by Jefferies with a new price target

      Jefferies downgraded Arvinas from Buy to Hold and set a new price target of $10.00

      5/2/25 8:06:16 AM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care